Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer

Pancreatic adenocarcinoma (PDAC) remains largely refractory to chemotherapeutic treatment regimens and, consequently, has the worst survival rate of all cancers. The low efficacy of current treatments results largely from toxicity-dependent dose limitations and premature cessation of therapy. Recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Slapak, Etienne J., el Mandili, Mouad, Brink, Marieke S. Ten, Kros, Alexander, Bijlsma, Maarten F., Spek, C. Arnold
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341742/
https://www.ncbi.nlm.nih.gov/pubmed/37445886
http://dx.doi.org/10.3390/ijms241310704

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10341742/
https://www.ncbi.nlm.nih.gov/pubmed/37445886
http://dx.doi.org/10.3390/ijms241310704

Ejemplares similares